{"ticker": {"uuid": "50d1a35f-0135-4320-9d90-d0b1d41840b9", "symbol": "LBRX", "name": "LB Pharmaceuticals Inc Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of \"Moderate Buy\" from Brokerages", "summary": "LB Pharmaceuticals Inc (NASDAQ:LBRX) has received a consensus \"Moderate Buy\" rating from nine brokerages, with an average 1-year price target of $39.50. The stock recently traded near its 52-week high at $32.95 and reported a better-than-expected quarterly loss. Several analysts ", "url": "https://www.marketbeat.com/instant-alerts/lb-pharmaceuticals-inc-nasdaqlbrx-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:40:09", "published_display": "12 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into Focus - Wyckoff Spring", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQbXpSNTZiSEl3Yy14cS10RTJQdG5BdGtmUXZMWmJIeEo1Z3BHWVFNWHkwYlhYdVFrdTYxbG1SNjFCX0RuTV92M2JsVDRqUWJvcHo4dFl0bDFnT2l6Z003ckF3MWl2Q2xHUFMzVndkRk0tNTFFUENMaWZZMU1FTDFQQmxLd3dDMHVFdU1uZ19sNXZHR2RDV2l4djAzdjQ3OWxhX09vYVBtbUpzVTExZ1ZteGlxUFBDOG5hT245cXk2VEZwdk1yclBCVlVn?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-10T23:40:15+00:00", "published_display": "10 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations", "summary": "LB Pharmaceuticals Inc. has granted an equity award to Christopher Zergebel, its new Senior Vice President of Clinical Operations, consisting of an option to purchase 75,000 shares of common stock vesting over four years. This inducement grant aligns with Nasdaq Listing Rule 5635", "url": "https://www.quiverquant.com/news/LB+Pharmaceuticals+Grants+Inducement+Equity+Award+to+New+Senior+Vice+President+of+Clinical+Operations", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T21:50:00", "published_display": "10 Jul 2026 21:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule", "summary": "LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, 75,000 stock options as an inducement equity award. This grant, under Nasdaq Listing Rule 5635(c)(4), aims to attract key talent, with options vesting over four years at an ", "url": "https://pluang.com/en/news-feed/lb-pharmaceuticals-laporkan-pemberian-insentif-karyawan-baru-berdasarkan-nasdaq", "source_name": "Pluang", "published_at": "2026-07-10T21:40:23", "published_display": "10 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)", "summary": "LB Pharmaceuticals Inc. (Nasdaq: LBRX) announced an inducement grant of equity to Christopher Zergebel, their new Senior Vice President, Clinical Operations. Mr. Zergebel received an option to purchase 75,000 shares of common stock, vesting over four years, at an exercise price o", "url": "https://www.marketscreener.com/news/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-ce7f5edfdb8ffe20", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T20:40:23", "published_display": "10 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)", "summary": "LB Pharmaceuticals announced an inducement grant of 100,000 stock options to a new Vice President of Preclinical Development. The options, granted on July 10, 2026, have an exercise price of $2.49 per share, vest over four years, and were awarded outside of the company's 2024 Equ", "url": "https://www.moomoo.com/news/post/72798258/press-release-lb-pharmaceuticals-reports-inducement-grant-to-new-employee?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T20:40:23", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals (LBRX.US) with a Buy rating. The firm has set a price target of $45 for the company's shares. This initiation and target price suggest a positive outlook from Wolfe Research on LB Pharmaceuticals' future performance.", "url": "https://www.moomoo.com/news/post/72580506/wolfe-research-initiates-lb-pharmaceuticals-lbrxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-08T05:40:34", "published_display": "08 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates LB Pharmaceuticals stock with outperform rating", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a $45.00 price target. The firm is optimistic about LB-102, a next-generation antipsychotic in development, which has shown efficacy and a favorable safety profile in Phase", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-lb-pharmaceuticals-stock-with-outperform-rating-93CH-4778648", "source_name": "Investing.com", "published_at": "2026-07-07T17:42:02", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a price target of $45.00, citing the potential of its drug LB-102 for schizophrenia and mood disorders. The company's stock has seen a significant return since its IPO in S", "url": "https://m.in.investing.com/news/stock-market-news/wolfe-research-initiates-lb-pharmaceuticals-stock-with-outperform-rating-93CH-5484829?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-07T10:10:34", "published_display": "07 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX - LB Pharmaceuticals Inc Dividends", "summary": "This article provides a detailed financial overview of LB Pharmaceuticals Inc (LBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also highlights key performance indicators such as EPS, insider/institutional ownership, ", "url": "https://finviz.com/stock?t=LBRX&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-04T15:08:59", "published_display": "04 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVTNvMlBNN3hqRC0wOVZKalVDR3VSbnFqZmVoVHd2bjBRcDh6QTBFbkdTZHFiNE9UVkEtU1c3TGU1N1VvX1JqTHhjWjVYcEQ5bk1hR0Fta1RJTVlfQW13eW5jTnliQnFVWWJuRThpSzRuWkJsVldQSXd5SVgwUWwyWC1ZZDEzaVdLdW9DSFZWUDNDWDZFNWEtbzF0RnZCMzg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations", "summary": "LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of global development operations experience and will be instrumental in advancing the company's multiple clinical programs for LB-102, which inc", "url": "https://www.sahmcapital.com/news/content/lb-pharmaceuticals-appoints-christopher-zergebel-as-senior-vice-president-clinical-operations-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T19:12:34", "published_display": "01 Jul 2026 19:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com", "summary": "LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, bringing over 25 years of global development operations experience. The company, which trades under NASDAQ:LBRX, is currently conducting Phase 3 and Phase 2 trials for neurop", "url": "https://ng.investing.com/news/stock-market-news/lb-pharmaceuticals-names-christopher-zergebel-as-svp-93CH-2580099", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T03:39:13", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "This article lists the top five up-and-coming pharmaceutical stocks, focusing on LB Pharmaceuticals Inc. (NASDAQ: LBRX), which is developing neuropsychiatric therapies. The company recently reported its Q1 2026 financial results, showing increased R&D and general administrative e", "url": "https://www.insidermonkey.com/blog/5-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792771/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T22:10:11", "published_display": "30 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals names Christopher Zergebel as SVP", "summary": "LB Pharmaceuticals Inc. (NASDAQ: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of experience to the biopharmaceutical company, which is advancing therapies for neuropsychiatric disorders, including a lead pro", "url": "https://www.investing.com/news/company-news/lb-pharmaceuticals-names-christopher-zergebel-as-svp-93CH-4767811", "source_name": "Investing.com", "published_at": "2026-06-30T13:09:38", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals taps veteran operator as 3 LB-102 trials advance", "summary": "LB Pharmaceuticals (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, to bolster its leadership as it advances multiple clinical programs for its lead candidate, LB-102. Zergebel brings over 25 years of global development operations e", "url": "https://www.stocktitan.net/news/LBRX/lb-pharmaceuticals-appoints-christopher-zergebel-as-senior-vice-lup3xeg2v1g8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:38", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total assets of LB Pharmaceuticals Inc \u2013 NASDAQ:LBRX", "summary": "The article focuses on the total assets of LB Pharmaceuticals Inc (NASDAQ: LBRX), noting that the market is closed with no trades. It provides a brief overview of the company's financial information, sourced from TradingView. The page primarily navigates through various sections ", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/financials-balance-sheet/total-assets/", "source_name": "TradingView", "published_at": "2026-06-30T00:41:23", "published_display": "30 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX)", "summary": "This article provides an overview of LB Pharmaceuticals Inc. (NASDAQ: LBRX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, upcoming earnings reports, recent e", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:59", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings, earnings, revenue, and stock performance data. It highlights that 7 analysts offer a 1-year price forecast for LBRX, with a max estimate of $78.00 and a min estimate of", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:59", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQX0ZoZkdZdlYxMFotNlBJdWVRQVc0akpZSkdkcjkyZmN3Y3hZZDJFX0wtaTR0emZtYmFvRkhZeTMwc2RINjllcVh0M01aLTEyOWllemd6c3FiOVFjRjQzRVlyTk12RXhVb2VOOEJQREIzQVdQT2k3TnF6cTFHWUhSbzBfdTdXMVlGUHkzV24zSGRGbk4wVXdrSjFTNEg5RXNVRV9LYV9QU0owX3hlX3BJcTEzVzZvQ2lL?oc=5", "source_name": "Moomoo", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NasdaqGM:LBRX) Stock Forecast & Analyst Predictions", "summary": "LB Pharmaceuticals's earnings are projected to decline by 25.7% per annum, while revenue is expected to grow by 79.8% annually, but the company is forecast to remain unprofitable for the next three years. The article also details recent company announcements, including the resign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lbrx/lb-pharmaceuticals/future", "source_name": "Simply Wall Street", "published_at": "2026-06-22T13:10:15", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright", "summary": "H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for LB Pharmaceuticals Inc (NASDAQ:LBRX), citing strong analyst support for its lead drug candidate, LB-102. Expert panels at a recent conference highlighted LB-102's potential for schizophrenia and depression ", "url": "https://www.investing.com/news/analyst-ratings/lb-pharmaceuticals-stock-rating-maintained-at-buy-by-hc-wainwright-93CH-4752432", "source_name": "Investing.com", "published_at": "2026-06-22T12:40:36", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Institutional Confidence", "summary": "This article provides an overview of institutional confidence in LB Pharmaceuticals Inc (LBRX), detailing key institutional shareholders and their recent activity. It lists major holders like Deep Track Capital LP and RA Capital Management, LP, along with their shares held and pe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:17", "published_display": "18 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings and EPS predictions. Based on 6 analysts, the current rating for LBRX is \"Buy\" with a target price indicating a 62.69% upside. The report also highlights past EPS performance a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:17", "published_display": "17 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for LB Pharmaceuticals Inc (LBRX), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The company closed at $30.050, up 8.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:17", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of LB Pharmaceuticals Inc (LBRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:40", "published_display": "17 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for LB Pharmaceuticals Inc (LBRX), including business segments, regional revenue, and profit contribution. However, the data necessary for this analysis has not been disclosed by the company. Consequently, the a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:40", "published_display": "17 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] LB PHARMACEUTICALS INC Reports Material Event", "summary": "LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D., has resigned her officer role effective June 15, 2026, for personal reasons but will transition to an advisor position. She will provide full-time consulting services until September 15, 2026, while th", "url": "https://www.stocktitan.net/sec-filings/LBRX/8-k-lb-pharmaceuticals-inc-reports-material-event-75c77970c340.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:40:35", "published_display": "10 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOUmZRcDA2SUNSdTFrMUFQbGtfdmFnSVYzdEMtOC1DbWhqZ292elVvMnBmRU92ZFlBd01ZQzhReEM3Snp3NEhKZzJDZDNtaUJHRnJWZ1RCeTlTWmU2SGpYMzlNY01QblhIdDBmSExpcU5OdXNhQTdhNTRHV2RTWEs3ZXV4a3hjQkxZWU9iZl9RQ2JJOVp6OXJhZDFRY2JZVkN6SlV2WXZfbWJ5RG5OMHY1Mk44a0ZsajQ1Nk81UzlmSm9jWnFSQTBHVUYzcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals to Participate in Upcoming June Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lb-pharmaceuticals-participate-upcoming-june-200500972.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObEJXR3JobmFPTXVBYzNmcGZvbGlpSzFrd2pxRFhVNGZtaS1kRGVrNmlYVWprRFRKeGlLQ2VuVVhHdG9hc0ZxUG1Kc2VYekpZS2ZoUU9zX1VfSVNZSmxwbEtjV2dvaDdJMEVfUTNzajhFMkJJdzM0b193SXptMlZYU291SFFhejV5aF9vU3YxajZNN1ZmX0RPRjFxWnFVcVZCV0dSNll0TE1HWDk2YW5sdk1VeWo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZTF5TlhyeW5jQ2FMZUQycm81RUpudHJsT3Z2LTRER0s4bnBqSEg2OTdrdXhiMVN5ZTdfc0M1SXM1YWJQSUE3RFROeVQydVFfX3BLSUxMYk1MeV9aRGlQS1gwYjQwaWt0b3Bfa0FNSkxBWUdfQXVreFdBRVd0eGtyN0RYMXNhM0FBejJaRWxRT1hPZjVqaFZBakZUWGw3Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQzUtWUxPeC1GanNlQmJ3UkxtZG1NS0cweUlJOWM4YldOVnpjaVI2TFFrSzFyeFVxOXhYWjBvWUlHU015cTRGM0hmWjV3d0JFclFoMzFxbXVOSC15UmpvZlBfRUhXU0dSS3NGS05rT2g1RmRYdEI1U0dTbTJJejVFUXJSWFYwZnlRbU83aF9ZN0FJbENuWE0wOTMtSUh6ZGNqczRESTZJTlRMbkFRRkJRY1BERlZIMElUelR5RGRaRmJGNVB5?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc.: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/lb-pharmaceuticals-inc-q1-earnings-201519437.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:15:19+00:00", "published_display": "12 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lb-pharmaceuticals-reports-first-quarter-200500240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New schizophrenia and bipolar trials backed by $365.6M at LB Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOLVRxcF9mZGQwakF5RkRvMExNQjRVWWNQWFFBWmN2LUNZeVQtU0JITnM5Nk5wN2MwMmhkdGRSRjU0WU84UnRrLXZrcVlxREVFSU1tY0FwNG9WNTVtVE9Uc2R3anphOWRKQzY3YzhNTEw1R2R3WWV4MnlIRHFrLVdOUEdDempRTkcxUExWZU4wWmpkT2s5QWlIeWRYUUdaSkFXTDZfM0RpcU9nOG1Sck9jcXFONVNySW9VVnAtaGc0Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Coverage on LB Pharmaceuticals With Buy Rating, $45 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-coverage-lb-112147558.html", "source_name": "MT Newswires", "published_at": "2026-04-27T11:21:47+00:00", "published_display": "27 Apr 2026 11:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new leaders at LB Pharmaceuticals receive stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOd1ExLVl2VGgyTXBXb1IyQTA0ZzlrUVRMSy0zZmh6VFM2VXQ5RElsWWVfSVpVU3FnamVWNnRYZXRaaG1VVXNFXzI0TnBXRUxfamwwWUhaMGM5YUNObjB4YnJaVU5tU3dycjluaGI3YXMzZG92emxmT1FtQlVMX3otdmkyd2JhYlZsM0lUVE5SeE14b0J3WDg4dTN1cEljLXlaVUxGemlTa3ZBV0pGODFGTzZESE0teHVJcEFsaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX Stock Price and Chart \u2014 NASDAQ:LBRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE03empBdVZqZ1lhMmhBZGw0bkxHYVFHU0hRczB6RkxBRFl4dERtNHdWcExJaVFtQWdEZGczZG9BWEVtQ3poMm14bUpJTTI1RTVfaHZTenMtNUc2U3BU?oc=5", "source_name": "TradingView", "published_at": "2025-09-11T18:41:50+00:00", "published_display": "11 Sep 2025 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9KQzVta3Z5bDlnQzVFUllrd3FONE9Vc09pbVhuVVY4X0dSQzkzXzBrTEd0Z2lnRk1NSENyNmRFanItZ2FfV1prZy1KVDVXQTRq?oc=5", "source_name": "CNN", "published_at": "2025-09-09T16:15:21+00:00", "published_display": "09 Sep 2025 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of \"Moderate Buy\" from Brokerages", "summary": "LB Pharmaceuticals Inc (NASDAQ:LBRX) has received a consensus \"Moderate Buy\" rating from nine brokerages, with an average 1-year price target of $39.50. The stock recently traded near its 52-week high at $32.95 and reported a better-than-expected quarterly loss. Several analysts ", "url": "https://www.marketbeat.com/instant-alerts/lb-pharmaceuticals-inc-nasdaqlbrx-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:40:09", "published_display": "12 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into Focus - Wyckoff Spring", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQbXpSNTZiSEl3Yy14cS10RTJQdG5BdGtmUXZMWmJIeEo1Z3BHWVFNWHkwYlhYdVFrdTYxbG1SNjFCX0RuTV92M2JsVDRqUWJvcHo4dFl0bDFnT2l6Z003ckF3MWl2Q2xHUFMzVndkRk0tNTFFUENMaWZZMU1FTDFQQmxLd3dDMHVFdU1uZ19sNXZHR2RDV2l4djAzdjQ3OWxhX09vYVBtbUpzVTExZ1ZteGlxUFBDOG5hT245cXk2VEZwdk1yclBCVlVn?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-10T23:40:15+00:00", "published_display": "10 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations", "summary": "LB Pharmaceuticals Inc. has granted an equity award to Christopher Zergebel, its new Senior Vice President of Clinical Operations, consisting of an option to purchase 75,000 shares of common stock vesting over four years. This inducement grant aligns with Nasdaq Listing Rule 5635", "url": "https://www.quiverquant.com/news/LB+Pharmaceuticals+Grants+Inducement+Equity+Award+to+New+Senior+Vice+President+of+Clinical+Operations", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T21:50:00", "published_display": "10 Jul 2026 21:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule", "summary": "LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, 75,000 stock options as an inducement equity award. This grant, under Nasdaq Listing Rule 5635(c)(4), aims to attract key talent, with options vesting over four years at an ", "url": "https://pluang.com/en/news-feed/lb-pharmaceuticals-laporkan-pemberian-insentif-karyawan-baru-berdasarkan-nasdaq", "source_name": "Pluang", "published_at": "2026-07-10T21:40:23", "published_display": "10 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)", "summary": "LB Pharmaceuticals Inc. (Nasdaq: LBRX) announced an inducement grant of equity to Christopher Zergebel, their new Senior Vice President, Clinical Operations. Mr. Zergebel received an option to purchase 75,000 shares of common stock, vesting over four years, at an exercise price o", "url": "https://www.marketscreener.com/news/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-ce7f5edfdb8ffe20", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T20:40:23", "published_display": "10 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)", "summary": "LB Pharmaceuticals announced an inducement grant of 100,000 stock options to a new Vice President of Preclinical Development. The options, granted on July 10, 2026, have an exercise price of $2.49 per share, vest over four years, and were awarded outside of the company's 2024 Equ", "url": "https://www.moomoo.com/news/post/72798258/press-release-lb-pharmaceuticals-reports-inducement-grant-to-new-employee?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T20:40:23", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals (LBRX.US) with a Buy rating. The firm has set a price target of $45 for the company's shares. This initiation and target price suggest a positive outlook from Wolfe Research on LB Pharmaceuticals' future performance.", "url": "https://www.moomoo.com/news/post/72580506/wolfe-research-initiates-lb-pharmaceuticals-lbrxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-08T05:40:34", "published_display": "08 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates LB Pharmaceuticals stock with outperform rating", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a $45.00 price target. The firm is optimistic about LB-102, a next-generation antipsychotic in development, which has shown efficacy and a favorable safety profile in Phase", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-lb-pharmaceuticals-stock-with-outperform-rating-93CH-4778648", "source_name": "Investing.com", "published_at": "2026-07-07T17:42:02", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com", "summary": "Wolfe Research has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a price target of $45.00, citing the potential of its drug LB-102 for schizophrenia and mood disorders. The company's stock has seen a significant return since its IPO in S", "url": "https://m.in.investing.com/news/stock-market-news/wolfe-research-initiates-lb-pharmaceuticals-stock-with-outperform-rating-93CH-5484829?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-07T10:10:34", "published_display": "07 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX - LB Pharmaceuticals Inc Dividends", "summary": "This article provides a detailed financial overview of LB Pharmaceuticals Inc (LBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also highlights key performance indicators such as EPS, insider/institutional ownership, ", "url": "https://finviz.com/stock?t=LBRX&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-04T15:08:59", "published_display": "04 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVTNvMlBNN3hqRC0wOVZKalVDR3VSbnFqZmVoVHd2bjBRcDh6QTBFbkdTZHFiNE9UVkEtU1c3TGU1N1VvX1JqTHhjWjVYcEQ5bk1hR0Fta1RJTVlfQW13eW5jTnliQnFVWWJuRThpSzRuWkJsVldQSXd5SVgwUWwyWC1ZZDEzaVdLdW9DSFZWUDNDWDZFNWEtbzF0RnZCMzg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations", "summary": "LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of global development operations experience and will be instrumental in advancing the company's multiple clinical programs for LB-102, which inc", "url": "https://www.sahmcapital.com/news/content/lb-pharmaceuticals-appoints-christopher-zergebel-as-senior-vice-president-clinical-operations-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T19:12:34", "published_display": "01 Jul 2026 19:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com", "summary": "LB Pharmaceuticals Inc. has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, bringing over 25 years of global development operations experience. The company, which trades under NASDAQ:LBRX, is currently conducting Phase 3 and Phase 2 trials for neurop", "url": "https://ng.investing.com/news/stock-market-news/lb-pharmaceuticals-names-christopher-zergebel-as-svp-93CH-2580099", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T03:39:13", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "This article lists the top five up-and-coming pharmaceutical stocks, focusing on LB Pharmaceuticals Inc. (NASDAQ: LBRX), which is developing neuropsychiatric therapies. The company recently reported its Q1 2026 financial results, showing increased R&D and general administrative e", "url": "https://www.insidermonkey.com/blog/5-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792771/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T22:10:11", "published_display": "30 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals names Christopher Zergebel as SVP", "summary": "LB Pharmaceuticals Inc. (NASDAQ: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations. Zergebel brings over 25 years of experience to the biopharmaceutical company, which is advancing therapies for neuropsychiatric disorders, including a lead pro", "url": "https://www.investing.com/news/company-news/lb-pharmaceuticals-names-christopher-zergebel-as-svp-93CH-4767811", "source_name": "Investing.com", "published_at": "2026-06-30T13:09:38", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals taps veteran operator as 3 LB-102 trials advance", "summary": "LB Pharmaceuticals (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, to bolster its leadership as it advances multiple clinical programs for its lead candidate, LB-102. Zergebel brings over 25 years of global development operations e", "url": "https://www.stocktitan.net/news/LBRX/lb-pharmaceuticals-appoints-christopher-zergebel-as-senior-vice-lup3xeg2v1g8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:38", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total assets of LB Pharmaceuticals Inc \u2013 NASDAQ:LBRX", "summary": "The article focuses on the total assets of LB Pharmaceuticals Inc (NASDAQ: LBRX), noting that the market is closed with no trades. It provides a brief overview of the company's financial information, sourced from TradingView. The page primarily navigates through various sections ", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/financials-balance-sheet/total-assets/", "source_name": "TradingView", "published_at": "2026-06-30T00:41:23", "published_display": "30 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX)", "summary": "This article provides an overview of LB Pharmaceuticals Inc. (NASDAQ: LBRX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, upcoming earnings reports, recent e", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:59", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings, earnings, revenue, and stock performance data. It highlights that 7 analysts offer a 1-year price forecast for LBRX, with a max estimate of $78.00 and a min estimate of", "url": "https://www.tradingview.com/symbols/NASDAQ-LBRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:59", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQX0ZoZkdZdlYxMFotNlBJdWVRQVc0akpZSkdkcjkyZmN3Y3hZZDJFX0wtaTR0emZtYmFvRkhZeTMwc2RINjllcVh0M01aLTEyOWllemd6c3FiOVFjRjQzRVlyTk12RXhVb2VOOEJQREIzQVdQT2k3TnF6cTFHWUhSbzBfdTdXMVlGUHkzV24zSGRGbk4wVXdrSjFTNEg5RXNVRV9LYV9QU0owX3hlX3BJcTEzVzZvQ2lL?oc=5", "source_name": "Moomoo", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NasdaqGM:LBRX) Stock Forecast & Analyst Predictions", "summary": "LB Pharmaceuticals's earnings are projected to decline by 25.7% per annum, while revenue is expected to grow by 79.8% annually, but the company is forecast to remain unprofitable for the next three years. The article also details recent company announcements, including the resign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lbrx/lb-pharmaceuticals/future", "source_name": "Simply Wall Street", "published_at": "2026-06-22T13:10:15", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright", "summary": "H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for LB Pharmaceuticals Inc (NASDAQ:LBRX), citing strong analyst support for its lead drug candidate, LB-102. Expert panels at a recent conference highlighted LB-102's potential for schizophrenia and depression ", "url": "https://www.investing.com/news/analyst-ratings/lb-pharmaceuticals-stock-rating-maintained-at-buy-by-hc-wainwright-93CH-4752432", "source_name": "Investing.com", "published_at": "2026-06-22T12:40:36", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Institutional Confidence", "summary": "This article provides an overview of institutional confidence in LB Pharmaceuticals Inc (LBRX), detailing key institutional shareholders and their recent activity. It lists major holders like Deep Track Capital LP and RA Capital Management, LP, along with their shares held and pe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:17", "published_display": "18 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for LB Pharmaceuticals Inc (LBRX), detailing analyst ratings and EPS predictions. Based on 6 analysts, the current rating for LBRX is \"Buy\" with a target price indicating a 62.69% upside. The report also highlights past EPS performance a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:17", "published_display": "17 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for LB Pharmaceuticals Inc (LBRX), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The company closed at $30.050, up 8.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:17", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of LB Pharmaceuticals Inc (LBRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:40", "published_display": "17 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for LB Pharmaceuticals Inc (LBRX), including business segments, regional revenue, and profit contribution. However, the data necessary for this analysis has not been disclosed by the company. Consequently, the a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lbrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:40", "published_display": "17 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] LB PHARMACEUTICALS INC Reports Material Event", "summary": "LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D., has resigned her officer role effective June 15, 2026, for personal reasons but will transition to an advisor position. She will provide full-time consulting services until September 15, 2026, while th", "url": "https://www.stocktitan.net/sec-filings/LBRX/8-k-lb-pharmaceuticals-inc-reports-material-event-75c77970c340.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:40:35", "published_display": "10 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOUmZRcDA2SUNSdTFrMUFQbGtfdmFnSVYzdEMtOC1DbWhqZ292elVvMnBmRU92ZFlBd01ZQzhReEM3Snp3NEhKZzJDZDNtaUJHRnJWZ1RCeTlTWmU2SGpYMzlNY01QblhIdDBmSExpcU5OdXNhQTdhNTRHV2RTWEs3ZXV4a3hjQkxZWU9iZl9RQ2JJOVp6OXJhZDFRY2JZVkN6SlV2WXZfbWJ5RG5OMHY1Mk44a0ZsajQ1Nk81UzlmSm9jWnFSQTBHVUYzcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals to Participate in Upcoming June Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lb-pharmaceuticals-participate-upcoming-june-200500972.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObEJXR3JobmFPTXVBYzNmcGZvbGlpSzFrd2pxRFhVNGZtaS1kRGVrNmlYVWprRFRKeGlLQ2VuVVhHdG9hc0ZxUG1Kc2VYekpZS2ZoUU9zX1VfSVNZSmxwbEtjV2dvaDdJMEVfUTNzajhFMkJJdzM0b193SXptMlZYU291SFFhejV5aF9vU3YxajZNN1ZmX0RPRjFxWnFVcVZCV0dSNll0TE1HWDk2YW5sdk1VeWo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZTF5TlhyeW5jQ2FMZUQycm81RUpudHJsT3Z2LTRER0s4bnBqSEg2OTdrdXhiMVN5ZTdfc0M1SXM1YWJQSUE3RFROeVQydVFfX3BLSUxMYk1MeV9aRGlQS1gwYjQwaWt0b3Bfa0FNSkxBWUdfQXVreFdBRVd0eGtyN0RYMXNhM0FBejJaRWxRT1hPZjVqaFZBakZUWGw3Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQzUtWUxPeC1GanNlQmJ3UkxtZG1NS0cweUlJOWM4YldOVnpjaVI2TFFrSzFyeFVxOXhYWjBvWUlHU015cTRGM0hmWjV3d0JFclFoMzFxbXVOSC15UmpvZlBfRUhXU0dSS3NGS05rT2g1RmRYdEI1U0dTbTJJejVFUXJSWFYwZnlRbU83aF9ZN0FJbENuWE0wOTMtSUh6ZGNqczRESTZJTlRMbkFRRkJRY1BERlZIMElUelR5RGRaRmJGNVB5?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Inc.: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/lb-pharmaceuticals-inc-q1-earnings-201519437.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:15:19+00:00", "published_display": "12 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lb-pharmaceuticals-reports-first-quarter-200500240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New schizophrenia and bipolar trials backed by $365.6M at LB Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOLVRxcF9mZGQwakF5RkRvMExNQjRVWWNQWFFBWmN2LUNZeVQtU0JITnM5Nk5wN2MwMmhkdGRSRjU0WU84UnRrLXZrcVlxREVFSU1tY0FwNG9WNTVtVE9Uc2R3anphOWRKQzY3YzhNTEw1R2R3WWV4MnlIRHFrLVdOUEdDempRTkcxUExWZU4wWmpkT2s5QWlIeWRYUUdaSkFXTDZfM0RpcU9nOG1Sck9jcXFONVNySW9VVnAtaGc0Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Coverage on LB Pharmaceuticals With Buy Rating, $45 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-coverage-lb-112147558.html", "source_name": "MT Newswires", "published_at": "2026-04-27T11:21:47+00:00", "published_display": "27 Apr 2026 11:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new leaders at LB Pharmaceuticals receive stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOd1ExLVl2VGgyTXBXb1IyQTA0ZzlrUVRMSy0zZmh6VFM2VXQ5RElsWWVfSVpVU3FnamVWNnRYZXRaaG1VVXNFXzI0TnBXRUxfamwwWUhaMGM5YUNObjB4YnJaVU5tU3dycjluaGI3YXMzZG92emxmT1FtQlVMX3otdmkyd2JhYlZsM0lUVE5SeE14b0J3WDg4dTN1cEljLXlaVUxGemlTa3ZBV0pGODFGTzZESE0teHVJcEFsaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LBRX Stock Price and Chart \u2014 NASDAQ:LBRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE03empBdVZqZ1lhMmhBZGw0bkxHYVFHU0hRczB6RkxBRFl4dERtNHdWcExJaVFtQWdEZGczZG9BWEVtQ3poMm14bUpJTTI1RTVfaHZTenMtNUc2U3BU?oc=5", "source_name": "TradingView", "published_at": "2025-09-11T18:41:50+00:00", "published_display": "11 Sep 2025 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9KQzVta3Z5bDlnQzVFUllrd3FONE9Vc09pbVhuVVY4X0dSQzkzXzBrTEd0Z2lnRk1NSENyNmRFanItZ2FfV1prZy1KVDVXQTRq?oc=5", "source_name": "CNN", "published_at": "2025-09-09T16:15:21+00:00", "published_display": "09 Sep 2025 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 60, "sentiment_summary": {"positive": 28, "negative": 3, "neutral": 29, "score": 59, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 12.74, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 28, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 32.95, "latest_week": "2026-07-10", "one_week_move": -1.4, "four_week_move": 15.9, "twelve_week_move": 8.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.490988, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 42.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 70.2128, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.4% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 10}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.4% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of \"Moderate Buy\" from Brokerages"}], "updated_at": "2026-07-16T03:35:28.647077+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}